Literature DB >> 27542673

The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios.

Sandip Basu1, Vikas Ostwal2.   

Abstract

Entities:  

Keywords:  177Lu-DOTATATE; 68Ga-DOTATATE; Chemotherapy; FDG-PET/CT; Neuroendocrine tumor; Peptide receptor radionuclide therapy

Mesh：

Substances：

Year:  2016        PMID： 27542673     DOI： 10.1007/s00259-016-3497-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  7 in total

1.  Should grade of tracer uptake on somatostatin receptor-targeted imaging be the major determinant and break the barrier of histopathologic criteria for determining the suitability of Peptide receptor radionuclide therapy?

Authors:  Sandip Basu
Journal:  J Nucl Med       Date:  2013-09-26       Impact factor: 10.057

2.  Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  K Öberg; U Knigge; D Kwekkeboom; A Perren
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

3.  Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT.

Authors:  Sandip Basu; Bhawna Sirohi; Shailesh V Shrikhande
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-27       Impact factor: 9.236

4.  Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors?

Authors:  Sandip Basu; Vikas Ostwal
Journal:  Nucl Med Commun       Date:  2016-06       Impact factor: 1.690

Review 5.  PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Sandip Basu; Rohit Ranade; Vikas Ostwal; Shailesh V Shrikhande
Journal:  PET Clin       Date:  2016-04-25

Review 6.  Correlation and discordance of tumour proliferation index and molecular imaging characteristics and their implications for treatment decisions and outcome pertaining to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumour: developing a personalized model.

Authors:  Sandip Basu; Rohit Ranade; Pradeep Thapa
Journal:  Nucl Med Commun       Date:  2015-08       Impact factor: 1.690

Review 7.  Personalized treatment approach to gastroenteropancreatic neuroendocrine tumors: a medical oncologist's perspective.

Authors:  Davinder Paul; Vikas Ostwal; Subhadeep Bose; Sandip Basu; Sudeep Gupta
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-09       Impact factor: 2.566
  7 in total
  4 in total

Review 1.  Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

2.  Availability of both [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?

Authors:  Sandip Basu; Rahul V Parghane; Sharmila Banerjee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-18       Impact factor: 9.236

Review 3.  Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.

Authors:  Diletta Calabrò; Giulia Argalia; Valentina Ambrosini
Journal:  Diagnostics (Basel)       Date:  2020-12-07

Review 4.  How I treat neuroendocrine tumours.

Authors:  Barbara Kiesewetter; Markus Raderer
Journal:  ESMO Open       Date:  2020-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.